Shionogi
SGIOYDrugs in Pipeline
56
Phase 3 Programs
31
Upcoming Catalysts
5
Next Catalyst
Dec 2026
Market Overview
Stock performance and key metrics
5 upcoming, 0 past
Secutrelvir
SARS-CoV-2
Cefiderocol
Urinary Tract Infections
Ospemifene
Vaginal Dryness
Lusutrombopag
Chronic Liver Disease
S-217622
SARS-CoV-2 Infection
Baloxavir Marboxil
Influenza
CLONICEL (Clonidine HCl sustained release)
Attention Deficit Hyperactivity Disorder
S-268019-b
SARS-CoV-2
Pravafen
Combined Hyperlipidemia
Best Available Therapy
Healthcare-associated Pneumonia (HCAP)
Naldemedine
Opioid-induced Constipation
Oseltamivir
Influenza
Dolutegravir
Infection, Human Immunodeficiency Virus I
MCI-186
Acute Ischemic Stroke (AIS)
GSK1349572
Infection, Human Immunodeficiency Virus
Olorofim
Invasive Aspergillosis
MT-1186
Amyotrophic Lateral Sclerosis (ALS)
MCI-186 in open label phase
Amyotrophic Lateral Sclerosis (ALS)
Duloxetine 60 mg
Fibromyalgia
PSD502, contains a mixture of lidocaine and prilocaine
Premature Ejaculation
Duloxetine
Back Pain Lower Back Chronic
Duloxetine hydrochloride
Diabetic Neuropathies
Duloxetine hydrochloride - 40 mg
Diabetic Neuropathies
Dolutegravir 50 mg twice daily
HIV Infections
GSK1349572 (dolutegravir)
Infection, Human Immunodeficiency Virus I
Ospemifene 60Mg Oral Tablet
Atrophy
Ospemifene (Dose 1)
Atrophy
Ospemifene 30 mg
Atrophy
Oral Glycopyrrolate Liquid
Cerebral Palsy
Meropenem
Healthcare-associated Pneumonia (HCAP)
Ospemifene 60 mg
Atrophy
S-606001
Pompe Disease
S-555739 Dose 1
Seasonal Allergic Rhinitis
Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle)
Primary Biliary Cirrhosis
Ospemifene 5 mg
Atrophy
S-3304
Non Small Cell Lung Cancer
Velneperit 400 mg
Obesity
S-309309
Obesity
S-488210/S-488211
Bladder Cancer
S-892216
COVID-19
S-777469 400 mg
Atopic Dermatitis
Ensitrelvir
Long COVID
S-600918
Chronic Cough
S-337395
Respiratory Syncytial Virus Infections
S-531011
Solid Tumors
S-2367 (velneperit)
Obesity
Standard of Care
Gram-negative Bacterial Infections
S-2367 800 mg
Obesity
efavirenz
Infection, Human Immunodeficiency Virus
S-2367 1600 mg q.d. 54 Weeks
Obesity
Redasemtide
Acute Ischemic Stroke
GSK1265744 30mg
Infection, Human Immunodeficiency Virus
S-707106 Dose A
Type 2 Diabetes Mellitus
Sivopixant
Sleep Apnea
BPN14770
Jordan's Syndrome
50 mg S-777469
Atopic Dermatitis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Secutrelvir | Phase 3 | SARS-CoV-2 | - | - |
Cefiderocol | Phase 3 | Urinary Tract Infections | - | - |
Ospemifene | Phase 3 | Vaginal Dryness | - | - |
Lusutrombopag | Phase 3 | Chronic Liver Disease | - | - |
S-217622 | Phase 3 | SARS-CoV-2 Infection | - | - |
Baloxavir Marboxil | Phase 3 | Influenza | - | - |
CLONICEL (Clonidine HCl sustained release) | Phase 3 | Attention Deficit Hyperactivity Disorder | - | - |
S-268019-b | Phase 3 | SARS-CoV-2 | - | - |
Pravafen | Phase 3 | Combined Hyperlipidemia | - | - |
Best Available Therapy | Phase 3 | Healthcare-associated Pneumonia (HCAP) | - | - |
Naldemedine | Phase 3 | Opioid-induced Constipation | - | - |
Oseltamivir | Phase 3 | Influenza | - | - |
Dolutegravir | Phase 3 | Infection, Human Immunodeficiency Virus I | - | - |
MCI-186 | Phase 3 | Acute Ischemic Stroke (AIS) | - | - |
GSK1349572 | Phase 3 | Infection, Human Immunodeficiency Virus | - | - |
Olorofim | Phase 3 | Invasive Aspergillosis | - | - |
MT-1186 | Phase 3 | Amyotrophic Lateral Sclerosis (ALS) | - | - |
MCI-186 in open label phase | Phase 3 | Amyotrophic Lateral Sclerosis (ALS) | - | - |
Duloxetine 60 mg | Phase 3 | Fibromyalgia | - | - |
PSD502, contains a mixture of lidocaine and prilocaine | Phase 3 | Premature Ejaculation | - | - |
Duloxetine | Phase 3 | Back Pain Lower Back Chronic | - | - |
Duloxetine hydrochloride | Phase 3 | Diabetic Neuropathies | - | - |
Duloxetine hydrochloride - 40 mg | Phase 3 | Diabetic Neuropathies | - | - |
Dolutegravir 50 mg twice daily | Phase 3 | HIV Infections | - | - |
GSK1349572 (dolutegravir) | Phase 3 | Infection, Human Immunodeficiency Virus I | - | - |
Ospemifene 60Mg Oral Tablet | Phase 3 | Atrophy | - | - |
Ospemifene (Dose 1) | Phase 3 | Atrophy | - | - |
Ospemifene 30 mg | Phase 3 | Atrophy | - | - |
Oral Glycopyrrolate Liquid | Phase 3 | Cerebral Palsy | - | - |
Meropenem | Phase 3 | Healthcare-associated Pneumonia (HCAP) | - | - |
Ospemifene 60 mg | Phase 3 | Atrophy | - | - |
S-606001 | Phase 2 | Pompe Disease | - | - |
S-555739 Dose 1 | Phase 2 | Seasonal Allergic Rhinitis | - | - |
Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle) | Phase 2 | Primary Biliary Cirrhosis | - | - |
Ospemifene 5 mg | Phase 2 | Atrophy | - | - |
S-3304 | Phase 2 | Non Small Cell Lung Cancer | - | - |
Velneperit 400 mg | Phase 2 | Obesity | - | - |
S-309309 | Phase 2 | Obesity | - | - |
S-488210/S-488211 | Phase 2 | Bladder Cancer | - | - |
S-892216 | Phase 2 | COVID-19 | - | - |
S-777469 400 mg | Phase 2 | Atopic Dermatitis | - | - |
Ensitrelvir | Phase 2 | Long COVID | - | - |
S-600918 | Phase 2 | Chronic Cough | - | - |
S-337395 | Phase 2 | Respiratory Syncytial Virus Infections | - | - |
S-531011 | Phase 2 | Solid Tumors | - | - |
S-2367 (velneperit) | Phase 2 | Obesity | - | - |
Standard of Care | Phase 2 | Gram-negative Bacterial Infections | - | - |
S-2367 800 mg | Phase 2 | Obesity | - | - |
efavirenz | Phase 2 | Infection, Human Immunodeficiency Virus | - | - |
S-2367 1600 mg q.d. 54 Weeks | Phase 2 | Obesity | - | - |
Redasemtide | Phase 2 | Acute Ischemic Stroke | - | - |
GSK1265744 30mg | Phase 2 | Infection, Human Immunodeficiency Virus | - | - |
S-707106 Dose A | Phase 2 | Type 2 Diabetes Mellitus | - | - |
Sivopixant | Phase 2 | Sleep Apnea | - | - |
BPN14770 | Phase 2 | Jordan's Syndrome | - | - |
50 mg S-777469 | Phase 2 | Atopic Dermatitis | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Shionogi's drug pipeline?→
CatalystAlert tracks 56 drug candidates in Shionogi's (SGIOY) pipeline across Phase 3, Phase 2. Its lead program is Secutrelvir (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Shionogi's next FDA catalyst?→
Shionogi's (SGIOY) next tracked catalyst is a Phase 2 expected December 30, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SGIOY biotech catalysts?→
Add SGIOY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Shionogi's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.